Example of HIV Medicine format
Recent searches

Example of HIV Medicine format Example of HIV Medicine format Example of HIV Medicine format Example of HIV Medicine format Example of HIV Medicine format Example of HIV Medicine format Example of HIV Medicine format Example of HIV Medicine format Example of HIV Medicine format Example of HIV Medicine format Example of HIV Medicine format Example of HIV Medicine format Example of HIV Medicine format Example of HIV Medicine format Example of HIV Medicine format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
Look Inside
Example of HIV Medicine format Example of HIV Medicine format Example of HIV Medicine format Example of HIV Medicine format Example of HIV Medicine format Example of HIV Medicine format Example of HIV Medicine format Example of HIV Medicine format Example of HIV Medicine format Example of HIV Medicine format Example of HIV Medicine format Example of HIV Medicine format Example of HIV Medicine format Example of HIV Medicine format Example of HIV Medicine format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
open access Open Access
recommended Recommended

HIV Medicine — Template for authors

Publisher: Wiley
Categories Rank Trend in last 3 yrs
Health Policy #14 of 242 down down by 3 ranks
Pharmacology (medical) #50 of 246 down down by 8 ranks
Infectious Diseases #65 of 288 down down by 12 ranks
journal-quality-icon Journal quality:
High
calendar-icon Last 4 years overview: 362 Published Papers | 2161 Citations
indexed-in-icon Indexed in: Scopus
last-updated-icon Last updated: 21/06/2020
Related journals
Insights
General info
Top papers
Popular templates
Get started guide
Why choose from SciSpace
FAQ

Related Journals

open access Open Access
recommended Recommended

Oxford University Press

Quality:  
High
CiteRatio: 9.1
SJR: 2.124
SNIP: 1.646
open access Open Access
recommended Recommended

American Society for Microbiology

Quality:  
High
CiteRatio: 9.1
SJR: 2.07
SNIP: 1.44
open access Open Access
recommended Recommended

Elsevier

Quality:  
High
CiteRatio: 12.0
SJR: 1.454
SNIP: 1.438
open access Open Access

Elsevier

Quality:  
High
CiteRatio: 4.2
SJR: 1.004
SNIP: 1.705

Journal Performance & Insights

Impact Factor

CiteRatio

Determines the importance of a journal by taking a measure of frequency with which the average article in a journal has been cited in a particular year.

A measure of average citations received per peer-reviewed paper published in the journal.

3.556

5% from 2018

Impact factor for HIV Medicine from 2016 - 2019
Year Value
2019 3.556
2018 3.734
2017 2.932
2016 3.257
graph view Graph view
table view Table view

6.0

3% from 2019

CiteRatio for HIV Medicine from 2016 - 2020
Year Value
2020 6.0
2019 5.8
2018 5.3
2017 5.6
2016 6.0
graph view Graph view
table view Table view

insights Insights

  • Impact factor of this journal has decreased by 5% in last year.
  • This journal’s impact factor is in the top 10 percentile category.

insights Insights

  • CiteRatio of this journal has increased by 3% in last years.
  • This journal’s CiteRatio is in the top 10 percentile category.

SCImago Journal Rank (SJR)

Source Normalized Impact per Paper (SNIP)

Measures weighted citations received by the journal. Citation weighting depends on the categories and prestige of the citing journal.

Measures actual citations received relative to citations expected for the journal's category.

1.53

2% from 2019

SJR for HIV Medicine from 2016 - 2020
Year Value
2020 1.53
2019 1.494
2018 1.697
2017 1.394
2016 1.624
graph view Graph view
table view Table view

1.138

15% from 2019

SNIP for HIV Medicine from 2016 - 2020
Year Value
2020 1.138
2019 1.331
2018 0.994
2017 0.825
2016 0.915
graph view Graph view
table view Table view

insights Insights

  • SJR of this journal has increased by 2% in last years.
  • This journal’s SJR is in the top 10 percentile category.

insights Insights

  • SNIP of this journal has decreased by 15% in last years.
  • This journal’s SNIP is in the top 10 percentile category.

HIV Medicine

Guideline source: View

All company, product and service names used in this website are for identification purposes only. All product names, trademarks and registered trademarks are property of their respective owners.

Use of these names, trademarks and brands does not imply endorsement or affiliation. Disclaimer Notice

Wiley

HIV Medicine

HIV Medicine aims to provide an alternative outlet for publication of international research papers in the field of HIV Medicine, embracing clinical, pharmocological, epidemiological, ethical, preclinical and in vitro studies. In addition, the journal will commission reviews a...... Read More

Health Policy

Infectious Diseases

Pharmacology (medical)

Medicine

i
Last updated on
21 Jun 2020
i
ISSN
1464-2662
i
Impact Factor
High - 1.323
i
Acceptance Rate
18%
i
Open Access
Yes
i
Sherpa RoMEO Archiving Policy
Yellow faq
i
Plagiarism Check
Available via Turnitin
i
Endnote Style
Download Available
i
Bibliography Name
apa
i
Citation Type
Numbered
[25]
i
Bibliography Example
Beenakker, C.W.J. (2006) Specular andreev reflection in graphene.Phys. Rev. Lett., 97 (6), 067 007. URL 10.1103/PhysRevLett.97.067007.

Top papers written in this journal

Journal Article DOI: 10.1111/J.1468-1293.2008.00636.X
British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008
01 Jul 2005 - Hiv Medicine

Abstract:

The 2008 BHIVA Guidelines have been updated to incorporate all the new relevant information (including presentations at the 15th Conference on Retroviruses and Opportunistic Infections 2008) since the last iteration. The guidelines follow the methodology outlined below and all the peer-reviewed publications and important, pot... The 2008 BHIVA Guidelines have been updated to incorporate all the new relevant information (including presentations at the 15th Conference on Retroviruses and Opportunistic Infections 2008) since the last iteration. The guidelines follow the methodology outlined below and all the peer-reviewed publications and important, potentially treatment-changing abstracts from the last 2 years have been reviewed. The translation of data into clinical practice is often difficult even with the best possible evidence (i.e. two randomized controlled trials) because of trial design, inclusion criteria and precise surrogate marker endpoints (see Appendix). The recommendations based upon expert opinion have the least good evidence but perhaps provide an important reason for writing the guidelines to produce a consensual opinion about current practice. It must, however, be appreciated that such opinion is often wrong and should not stifle research to challenge it. Similarly, although the Writing Group seeks to provide guidelines to optimize treatment, such care needs to be individualized and we have not constructed a document that we would wish to see used as a ‘standard’ for litigation. read more read less
View PDF
1,107 Citations
open accessOpen access Journal Article DOI: 10.1046/J.1468-1293.2000.00012.X
Immune restoration disease after the treatment of immunodeficient HIV‐infected patients with highly active antiretroviral therapy
01 Apr 2000 - Hiv Medicine

Abstract:

Background: To determine if infectious disease events in HIV-infected patients treated with highly active antiretroviral therapy (HAART) are a consequence of the restoration of pathogen-specific immune responses, a single-centre retrospective study of all HIV-infected patients commencing HAART prior to 1 July 1997 was underta... Background: To determine if infectious disease events in HIV-infected patients treated with highly active antiretroviral therapy (HAART) are a consequence of the restoration of pathogen-specific immune responses, a single-centre retrospective study of all HIV-infected patients commencing HAART prior to 1 July 1997 was undertaken to determine the incidence, characteristics and time of onset of disease episodes in HAART responders (decrease in plasma HIV RNA of > 1 log10 copies/mL). Methods: Baseline and post-therapy changes in CD4 T-cell counts and HIV RNA were compared in patients with and without disease and delayed-type hypersensitivity responses to mycobacterial antigens were measured in selected patients. Results: Thirty-three of 132 HAART responders (25%) exhibited one or more disease episodes after HAART, related to a pre-existent or subclinical infection by an opportunistic pathogen. Disease episodes were most often related to infections by mycobacteria or herpesviruses but hepatitis C virus (HCV), molluscum contagiosum virus and human papilloma virus were also implicated. They were most common in patients with a baseline CD4 T-cell count of < 50/uL and occurred most often during the first 2 months of therapy and when CD4 T-cell counts were increasing. Mycobacteria- and HCV-related diseases were associated with restoration of pathogen-specific immune responses. Conclusions: We conclude that improved immune function in immunodeficient patients treated with HAART may restore pathogen-specific immune responses and cause inflammation in tissues infected by those pathogens. read more read less

Topics:

Subclinical infection (53%)53% related to the paper, Hepatitis C virus (51%)51% related to the paper, Disease (51%)51% related to the paper, Immune system (50%)50% related to the paper
424 Citations
open accessOpen access Journal Article DOI: 10.1111/J.1468-1293.2010.00857.X
Late presentation of HIV infection: a consensus definition
01 Jan 2011 - Hiv Medicine

Abstract:

Objectives Across Europe, almost a third of individuals infected with HIV do not enter health care until late in the course of their infection. Surveillance to identify the extent to which late presentation occurs remains inadequate across Europe and is further complicated by the lack of a common clinical definition of late p... Objectives Across Europe, almost a third of individuals infected with HIV do not enter health care until late in the course of their infection. Surveillance to identify the extent to which late presentation occurs remains inadequate across Europe and is further complicated by the lack of a common clinical definition of late presentation. The objective of this article is to present a consensus definition of late presentation of HIV infection. Methods Over the past year, two initiatives have moved towards a harmonized definition. In spring 2009, they joined efforts to identify a common definition of what is meant by a ‘late-presenting’ patient. Results Two definitions were agreed upon, as follows. Late presentation: persons presenting for care with a CD4 count below 350 cells/μL or presenting with an AIDS-defining event, regardless of the CD4 cell count. Presentation with advanced HIV disease: persons presenting for care with a CD4 count below 200 cells/μL or presenting with an AIDS-defining event, regardless of the CD4 cell count. Conclusion The European Late Presenter Consensus working group believe it would be beneficial if all national health agencies, institutions, and researchers were able to implement this definition (either on its own or alongside their own preferred definition) when reporting surveillance or research data relating to late presentation of HIV infection. read more read less

Topics:

Presentation (52%)52% related to the paper, Acquired immunodeficiency syndrome (AIDS) (51%)51% related to the paper
View PDF
408 Citations
open accessOpen access Journal Article DOI: 10.1111/J.1468-1293.2007.00533.X
European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults
Nathan Clumeck, Anton Pozniak, François Raffi
01 Feb 2008 - Hiv Medicine

Abstract:

A working group of the European AIDS Clinical Society (EACS) have developed these guidelines for European clinicians to help them in the treatment of adults with HIV infection. This third version of the guidelines includes, as new topics, the assessment of patients at initial and subsequent clinic visits as well as post-expos... A working group of the European AIDS Clinical Society (EACS) have developed these guidelines for European clinicians to help them in the treatment of adults with HIV infection. This third version of the guidelines includes, as new topics, the assessment of patients at initial and subsequent clinic visits as well as post-exposure prophylaxis. A revision of the 2005 guidelines based on current data includes changes in the sections on primary HIV infection, when to initiate therapy, which drug combinations are preferred as initial combination regimens for antiretroviral-naive patients, how to manage virological failure and the treatment of HIV during pregnancy. In Europe, there is a wide range of clinical practices in antiretroviral therapy depending on various factors such as drug registration, national policies, local availability, reimbursement and access to treatment. These can vary greatly from one country to another, especially in Central and Eastern parts of Europe. These guidelines are intended to help clinicians achieve the best care for their patients. In some countries, particularly where the quality of and access to care are not optimal, these guidelines should help AIDS societies and physicians or patient group organizations to negotiate with their national health authorities with a view to implementing what should be the standard of care for HIV-infected patients all over Europe. read more read less

Topics:

Acquired immunodeficiency syndrome (AIDS) (55%)55% related to the paper
398 Citations
Journal Article DOI: 10.1111/J.1468-1293.2012.00996.X
Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis.
Fakhrul Islam1, Jianyun Wu1, James Jansson1, David Wilson1
01 Sep 2012 - Hiv Medicine

Abstract:

Objectives The aim of this study was to estimate the relative risk of cardiovascular disease (CVD) among people living with HIV (PLHIV) compared with the HIV-uninfected population. Methods We conducted a systematic review and meta-analysis of studies from the peer-reviewed literature. We searched the Medline database for... Objectives The aim of this study was to estimate the relative risk of cardiovascular disease (CVD) among people living with HIV (PLHIV) compared with the HIV-uninfected population. Methods We conducted a systematic review and meta-analysis of studies from the peer-reviewed literature. We searched the Medline database for relevant journal articles published before August 2010. Eligible studies were observational and randomized controlled trials, reporting CVD, defined as myocardial infarction (MI), ischaemic heart disease, cardiovascular and cerebrovascular events or coronary heart disease among HIV-positive adults. Pooled relative risks were calculated for various groupings, including different classes of antiretroviral therapy (ART). Results The relative risk of CVD was 1.61 [95% confidence interval (CI) 1.43–1.81] among PLHIV without ART compared with HIV-uninfected people. The relative risk of CVD was 2.00 (95% CI 1.70–2.37) among PLHIV on ART compared with HIV-uninfected people and 1.52 (95% CI 1.35–1.70) compared with treatment-naive PLHIV. We estimate the relative risk of CVD associated with protease inhibitor (PI)-, nucleoside reverse transcriptase inhibitor- and nonnucleoside reverse transcriptase inhibitor-based ART to be 1.11 (95% CI 1.05–1.17), 1.05 (95% CI 1.01–1.10) and 1.04 (95% CI 0.99–1.09) per year of exposure, respectively. Not all ART was associated with increased risk; specifically, lopinavir/ritonavir and abacavir were associated with the greater risk and the relative risk of MI for PI-based versus non-PI-based ART was 1.41 (95% CI 1.20–1.65). Conclusion PLHIV are at increased risk of cardiovascular disease. Although effective in prolonging survival, ART (in particular PI-based regimens) is related to further increased risk of CVD events among people at highest initial absolute risk of cardiovascular disease. read more read less

Topics:

Absolute risk reduction (56%)56% related to the paper, Relative risk (55%)55% related to the paper, Population (51%)51% related to the paper
View PDF
381 Citations
Author Pic

SciSpace is a very innovative solution to the formatting problem and existing providers, such as Mendeley or Word did not really evolve in recent years.

- Andreas Frutiger, Researcher, ETH Zurich, Institute for Biomedical Engineering

Get MS-Word and LaTeX output to any Journal within seconds
1
Choose a template
Select a template from a library of 40,000+ templates
2
Import a MS-Word file or start fresh
It takes only few seconds to import
3
View and edit your final output
SciSpace will automatically format your output to meet journal guidelines
4
Submit directly or Download
Submit to journal directly or Download in PDF, MS Word or LaTeX

(Before submission check for plagiarism via Turnitin)

clock Less than 3 minutes

What to expect from SciSpace?

Speed and accuracy over MS Word

''

With SciSpace, you do not need a word template for HIV Medicine.

It automatically formats your research paper to Wiley formatting guidelines and citation style.

You can download a submission ready research paper in pdf, LaTeX and docx formats.

Time comparison

Time taken to format a paper and Compliance with guidelines

Plagiarism Reports via Turnitin

SciSpace has partnered with Turnitin, the leading provider of Plagiarism Check software.

Using this service, researchers can compare submissions against more than 170 million scholarly articles, a database of 70+ billion current and archived web pages. How Turnitin Integration works?

Turnitin Stats
Publisher Logos

Freedom from formatting guidelines

One editor, 100K journal formats – world's largest collection of journal templates

With such a huge verified library, what you need is already there.

publisher-logos

Easy support from all your favorite tools

HIV Medicine format uses apa citation style.

Automatically format and order your citations and bibliography in a click.

SciSpace allows imports from all reference managers like Mendeley, Zotero, Endnote, Google Scholar etc.

Frequently asked questions

1. Can I write HIV Medicine in LaTeX?

Absolutely not! Our tool has been designed to help you focus on writing. You can write your entire paper as per the HIV Medicine guidelines and auto format it.

2. Do you follow the HIV Medicine guidelines?

Yes, the template is compliant with the HIV Medicine guidelines. Our experts at SciSpace ensure that. If there are any changes to the journal's guidelines, we'll change our algorithm accordingly.

3. Can I cite my article in multiple styles in HIV Medicine?

Of course! We support all the top citation styles, such as APA style, MLA style, Vancouver style, Harvard style, and Chicago style. For example, when you write your paper and hit autoformat, our system will automatically update your article as per the HIV Medicine citation style.

4. Can I use the HIV Medicine templates for free?

Sign up for our free trial, and you'll be able to use all our features for seven days. You'll see how helpful they are and how inexpensive they are compared to other options, Especially for HIV Medicine.

5. Can I use a manuscript in HIV Medicine that I have written in MS Word?

Yes. You can choose the right template, copy-paste the contents from the word document, and click on auto-format. Once you're done, you'll have a publish-ready paper HIV Medicine that you can download at the end.

6. How long does it usually take you to format my papers in HIV Medicine?

It only takes a matter of seconds to edit your manuscript. Besides that, our intuitive editor saves you from writing and formatting it in HIV Medicine.

7. Where can I find the template for the HIV Medicine?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per HIV Medicine's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

8. Can I reformat my paper to fit the HIV Medicine's guidelines?

Of course! You can do this using our intuitive editor. It's very easy. If you need help, our support team is always ready to assist you.

9. HIV Medicine an online tool or is there a desktop version?

SciSpace's HIV Medicine is currently available as an online tool. We're developing a desktop version, too. You can request (or upvote) any features that you think would be helpful for you and other researchers in the "feature request" section of your account once you've signed up with us.

10. I cannot find my template in your gallery. Can you create it for me like HIV Medicine?

Sure. You can request any template and we'll have it setup within a few days. You can find the request box in Journal Gallery on the right side bar under the heading, "Couldn't find the format you were looking for like HIV Medicine?”

11. What is the output that I would get after using HIV Medicine?

After writing your paper autoformatting in HIV Medicine, you can download it in multiple formats, viz., PDF, Docx, and LaTeX.

12. Is HIV Medicine's impact factor high enough that I should try publishing my article there?

To be honest, the answer is no. The impact factor is one of the many elements that determine the quality of a journal. Few of these factors include review board, rejection rates, frequency of inclusion in indexes, and Eigenfactor. You need to assess all these factors before you make your final call.

13. What is Sherpa RoMEO Archiving Policy for HIV Medicine?

SHERPA/RoMEO Database

We extracted this data from Sherpa Romeo to help researchers understand the access level of this journal in accordance with the Sherpa Romeo Archiving Policy for HIV Medicine. The table below indicates the level of access a journal has as per Sherpa Romeo's archiving policy.

RoMEO Colour Archiving policy
Green Can archive pre-print and post-print or publisher's version/PDF
Blue Can archive post-print (ie final draft post-refereeing) or publisher's version/PDF
Yellow Can archive pre-print (ie pre-refereeing)
White Archiving not formally supported
FYI:
  1. Pre-prints as being the version of the paper before peer review and
  2. Post-prints as being the version of the paper after peer-review, with revisions having been made.

14. What are the most common citation types In HIV Medicine?

The 5 most common citation types in order of usage for HIV Medicine are:.

S. No. Citation Style Type
1. Author Year
2. Numbered
3. Numbered (Superscripted)
4. Author Year (Cited Pages)
5. Footnote

15. How do I submit my article to the HIV Medicine?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per HIV Medicine's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

16. Can I download HIV Medicine in Endnote format?

Yes, SciSpace provides this functionality. After signing up, you would need to import your existing references from Word or Bib file to SciSpace. Then SciSpace would allow you to download your references in HIV Medicine Endnote style according to Elsevier guidelines.

Fast and reliable,
built for complaince.

Instant formatting to 100% publisher guidelines on - SciSpace.

Available only on desktops 🖥

No word template required

Typset automatically formats your research paper to HIV Medicine formatting guidelines and citation style.

Verifed journal formats

One editor, 100K journal formats.
With the largest collection of verified journal formats, what you need is already there.

Trusted by academicians

I spent hours with MS word for reformatting. It was frustrating - plain and simple. With SciSpace, I can draft my manuscripts and once it is finished I can just submit. In case, I have to submit to another journal it is really just a button click instead of an afternoon of reformatting.

Andreas Frutiger
Researcher & Ex MS Word user
Use this template